Autolus Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	51.13	10.12	1.7	6.36	2.33	1.72
Revenue	51.13	10.12	1.7	6.36	2.33	1.72
Revenue Growth (YoY)	406.67%	496.00%	-73.30%	172.96%	35.86%	-41.02%
Cost of Revenue	186.51	141.02	122.31	117.35	110.84	134.89
Gross Profit	-135.38	-130.9	-120.62	-110.99	-108.51	-133.17
Selling, General & Admin	138.56	109.89	54.91	31.9	31.87	34.97
Operating Expenses	138.56	109.89	54.91	31.9	31.87	34.97
Operating Income	-273.94	-240.79	-175.53	-142.89	-140.37	-168.15
Interest Expense	-11.39	-9.29	-45.07	-8.91	-1.11	-
Interest & Investment Income	23.2	32.36	13.51	1.71	0.26	0.54
Currency Exchange Gain (Loss)	13.15	-0.99	2.64	1.8	-2.3	-0.2
Other Non Operating Income (Expenses)	28.9	0.32	0.22	0.34	0.16	1.55
EBT Excluding Unusual Items	-220.08	-218.4	-204.23	-147.95	-143.36	-166.26
Gain (Loss) on Sale of Assets	-0	-0.22	-3.79	-0.52	-0.68	-
Asset Writedown	-	-0.41	-0.38	-	-	-
Other Unusual Items	-0.1	-0.1	-	-0.1	2	-
Pretax Income	-220.19	-219.13	-208.4	-148.57	-142.04	-166.26
Income Tax Expense	4.62	1.53	-0.02	0.27	0.06	-24.16
Net Income	-224.8	-220.66	-208.38	-148.84	-142.1	-142.09
Net Income to Common	-224.8	-220.66	-208.38	-148.84	-142.1	-142.09
Shares Outstanding (Basic)	266	255	174	95	72	52
Shares Outstanding (Diluted)	266	255	174	95	72	52
Shares Change (YoY)	14.66%	46.69%	83.11%	31.78%	39.81%	19.72%
EPS (Basic)	-0.84	-0.86	-1.20	-1.57	-1.97	-2.76
EPS (Diluted)	-0.84	-0.86	-1.20	-1.57	-1.97	-2.76
Free Cash Flow	-285.22	-228.35	-156.57	-123.15	-126.72	-132.44
Free Cash Flow Per Share	-1.07	-0.90	-0.90	-1.30	-1.76	-2.57
Gross Margin	-264.79%	-	-	-	-	-
Operating Margin	-535.79%	-2379.34%	-10337.34%	-2246.74%	-6024.64%	-9804.37%
Profit Margin	-439.68%	-2180.45%	-12272.26%	-2340.24%	-6098.54%	-8285.36%
Free Cash Flow Margin	-557.85%	-2256.38%	-9221.02%	-1936.31%	-5438.54%	-7722.39%
EBITDA	-264.68	-233.07	-168.96	-135.54	-132.01	-162.58
D&A For EBITDA	9.26	7.72	6.57	7.36	8.37	5.57
EBIT	-273.94	-240.79	-175.53	-142.89	-140.37	-168.15
Revenue as Reported	51.13	10.12	1.7	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.